At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 388 enrolled
Drug / intervention
Insulin Peglispro +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open Label, Randomized, Parallel, 26 Week Treatment Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti Hyperglycemia Medications in Asian Insulin Naïve Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating Insulin Peglispro, Insulin Glargine, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 388 participants across 31 sites in 3 countries.
Detailed Summary
The purpose of this study is to compare insulin peglispro (LY2605541) to insulin glargine in Asian insulin naïve participants who have been treated with oral anti hyperglycemia medications. Participants will receive 26 weeks of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedJul 2013
Primary CompletionApr 2015
TodayJul 2026
First PostedJul 10, 2013
Enrollment StartJul 1, 2013
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.0 years ago
Interventions
Insulin Peglisprodrug
Administered SC using a prefilled pen.
Insulin Glarginedrug
Administered SC using a prefilled pen
Oral Antihyperglycemic Medications (OAMs)drug
Administered orally